When does this change take effect?

This change is effective Oct 15, 2025.

CommercialCoverageMedium impact

08.00.13al, Immune Globulin Intravenous (IVIG), Subcutaneous (SCIG)

Q: Who is affected by this change?

This affects Independence Blue Cross Allergy & Immunology, Neurology, Hematology, Oncology, Infectious Disease, Rheumatology providers on Commercial plans.

Independence Blue Cross·Allergy & Immunology, Neurology, Hematology +3 more·Medical Policy

Effective date

Oct 15, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

This is a reissued policy for Immune Globulin Intravenous (IVIG) and Subcutaneous (SCIG) treatments under commercial insurance plans. The policy has been updated and reposted as of October 15, 2025, but only summary information is currently available.

Action Required

Action needed

By October 15, 2025: Review the complete updated IVIG/SCIG policy at the provided URL to identify specific changes to coverage criteria, prior authorization requirements, or billing procedures. Compare with previous version to determine workflow impacts for immune globulin treatments.

Related policy hubs

Independence Blue Cross policies Allergy & Immunology Neurology Hematology Oncology Infectious Disease Rheumatology